Literature DB >> 26307863

The splenic injury outcomes trial: An American Association for the Surgery of Trauma multi-institutional study.

Ben L Zarzaur1, Rosemary Kozar, John G Myers, Jeffrey A Claridge, Thomas M Scalea, Todd A Neideen, Adrian A Maung, Louis Alarcon, Alain Corcos, Andrew Kerwin, Raul Coimbra.   

Abstract

BACKGROUND: Delayed splenic hemorrhage after nonoperative management (NOM) of blunt splenic injury (BSI) is a feared complication, particularly in the outpatient setting. Significant resources, including angiography (ANGIO), are used in an effort to prevent delayed splenectomy (DS). No prospective, long-term data exist to determine the actual risk of splenectomy. The purposes of this trial were to ascertain the 180-day risk of splenectomy after 24 hours of NOM of BSI and to determine factors related to splenectomy.
METHODS: Eleven Level I trauma centers participated in this prospective observational study. Adult patients achieving 24 hours of NOM of their BSI were eligible. Patients were followed up for 180 days. Demographic, physiologic, radiographic, injury-related information, and spleen-related interventions were recorded. Bivariate and multivariable analyses were used to determine factors associated with DS.
RESULTS: A total of 383 patients were enrolled. Twelve patients (3.1%) underwent in-hospital splenectomy between 24 hours and 9 days after injury. Of 366 discharged with a spleen, 1 (0.27%) required readmission for DS on postinjury Day 12. No Grade I injuries experienced DS. The splenectomy rate after 24 hours of NOM was 1.5 per 1,000 patient-days. Only extravasation from the spleen at time of admission (ADMIT-BLUSH) was associated with splenectomy (odds ratio, 3.6; 95% confidence interval, 1.4-12.4). Of patients with ADMIT-BLUSH (n = 49), 17 (34.7%) did not have ANGIO with embolization (EMBO), and 2 of those (11.8%) underwent splenectomy; 32 (65.3%) underwent ANGIO with EMBO, and 2 of those (6.3%, p = 0.6020 compared with no ANGIO with EMBO) required splenectomy.
CONCLUSION: Splenectomy after 24 hours of NOM is rare. After the initial 24 hours, no additional interventions are warranted for patients with Grade I injuries. For Grades II to V, close observation as an inpatient or outpatient is indicated for 10 days to 14 days. ADMIT-BLUSH is a strong predictor of DS and should lead to close observation or earlier surgical intervention. LEVEL OF EVIDENCE: Prognostic/epidemiological study, level III; therapeutic study, level IV.

Entities:  

Mesh:

Year:  2015        PMID: 26307863     DOI: 10.1097/TA.0000000000000782

Source DB:  PubMed          Journal:  J Trauma Acute Care Surg        ISSN: 2163-0755            Impact factor:   3.313


  16 in total

1.  Management of blunt splenic injury in a UK major trauma centre and predicting the failure of non-operative management: a retrospective, cross-sectional study.

Authors:  Stella R Smith; Louise Morris; Stephen Spreadborough; Waleed Al-Obaydi; Marta D'Auria; Hilary White; Adam J Brooks
Journal:  Eur J Trauma Emerg Surg       Date:  2017-06-09       Impact factor: 3.693

2.  Revised AAST scale for splenic injury (2018): does addition of arterial phase on CT have an impact on the grade?

Authors:  Naren Hemachandran; Shivanand Gamanagatti; Raju Sharma; Kathirkamanathan Shanmuganathan; Atin Kumar; Amit Gupta; Subodh Kumar
Journal:  Emerg Radiol       Date:  2020-07-23

Review 3.  Follow-up strategies for patients with splenic trauma managed non-operatively: the 2022 World Society of Emergency Surgery consensus document.

Authors:  Mauro Podda; Belinda De Simone; Marco Ceresoli; Francesco Virdis; Francesco Favi; Johannes Wiik Larsen; Federico Coccolini; Massimo Sartelli; Nikolaos Pararas; Solomon Gurmu Beka; Luigi Bonavina; Raffaele Bova; Adolfo Pisanu; Fikri Abu-Zidan; Zsolt Balogh; Osvaldo Chiara; Imtiaz Wani; Philip Stahel; Salomone Di Saverio; Thomas Scalea; Kjetil Soreide; Boris Sakakushev; Francesco Amico; Costanza Martino; Andreas Hecker; Nicola de'Angelis; Mircea Chirica; Joseph Galante; Andrew Kirkpatrick; Emmanouil Pikoulis; Yoram Kluger; Denis Bensard; Luca Ansaloni; Gustavo Fraga; Ian Civil; Giovanni Domenico Tebala; Isidoro Di Carlo; Yunfeng Cui; Raul Coimbra; Vanni Agnoletti; Ibrahima Sall; Edward Tan; Edoardo Picetti; Andrey Litvin; Dimitrios Damaskos; Kenji Inaba; Jeffrey Leung; Ronald Maier; Walt Biffl; Ari Leppaniemi; Ernest Moore; Kurinchi Gurusamy; Fausto Catena
Journal:  World J Emerg Surg       Date:  2022-10-12       Impact factor: 8.165

4.  Variation in intensive care unit utilization and mortality after blunt splenic injury.

Authors:  Elinore J Kaufman; Douglas J Wiebe; Niels D Martin; Jose L Pascual; Patrick M Reilly; Daniel N Holena
Journal:  J Surg Res       Date:  2016-03-30       Impact factor: 2.192

Review 5.  Evidence-Based Management and Controversies in Blunt Splenic Trauma.

Authors:  D C Olthof; C H van der Vlies; J C Goslings
Journal:  Curr Trauma Rep       Date:  2017-02-09

6.  National Readmission Patterns of Isolated Splenic Injuries Based on Initial Management Strategy.

Authors:  Graeme M Rosenberg; Lisa Knowlton; Charlotte Rajasingh; Yingjie Weng; Paul M Maggio; David A Spain; Kristan L Staudenmayer
Journal:  JAMA Surg       Date:  2017-12-01       Impact factor: 14.766

Review 7.  Splenic artery embolization: technically feasible but not necessarily advantageous.

Authors:  F Van der Cruyssen; A Manzelli
Journal:  World J Emerg Surg       Date:  2016-09-13       Impact factor: 5.469

8.  After the embo: predicting non-hemorrhagic indications for splenectomy after angioembolization in patients with blunt trauma.

Authors:  John F Bilello; Victoria L Sharp; Rachel C Dirks; Krista L Kaups; James W Davis
Journal:  Trauma Surg Acute Care Open       Date:  2018-02-05

Review 9.  An update on nonoperative management of the spleen in adults.

Authors:  Ben L Zarzaur; Grace S Rozycki
Journal:  Trauma Surg Acute Care Open       Date:  2017-06-09

Review 10.  Alternative clinical trial designs.

Authors:  John A Harvin; Ben L Zarzaur; Raminder Nirula; Benjamin T King; Ajai K Malhotra
Journal:  Trauma Surg Acute Care Open       Date:  2020-02-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.